Dempsey calls skincare peptides a promising little sister to retinoids for people 30 and up, but urges extreme caution with unapproved injectables.
Recap by typeshit. Full story at NewYork-Presbyterian.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
BioPharma APAC counts 12 generic makers since Novo's patent lapsed in March. Some vials run about Rs 1,300 a month, and generics hit half of sales by April.
The APA argues patients on GLP-1 treatment with clinical needs should get physio support to keep their strength, mobility and independence.
Loading…